Guardian Pharmacy Services, Inc. logo

Guardian Pharmacy Services, Inc.(GRDN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 4 days
PROFIT SINCE LAST BUY
-0.66% ▼
LAST CLOSE
$49.52
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GRDN

11/13/2026: GRDN (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Guardian Pharmacy Services, Inc. is a specialty healthcare stock that provides technology-enabled pharmacy services and medication management to long-term care facilities. The company benefits from a decentralized partnership model, proprietary software tools, and robust secular demand driven by an aging population. Its primary investment story centers on organic resident growth combined with disciplined regional acquisitions that expand operating scale. However, key risks include competitive pressures from healthcare goliaths and vulnerability to federal drug pricing regulations. The stock suits growth-oriented investors looking for exposure to senior care, with ongoing monitoring required around regulatory changes and M&A integration execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company delivers steady expansion in resident counts and revenue driven by secular aging trends.
Momentum investorStrong fit while signal remains positivePositive earnings updates and upwardly revised full-year guidance support favorable near-term stock momentum.
Value investorMixed fitValuation multiples reflect strong growth expectations, balancing against a premium price relative to traditional value benchmarks.
Dividend investorWeak fitGuardian prioritizes reinvesting capital into business expansion rather than paying significant dividends.
Low-risk investorMixed fitWhile the business provides essential healthcare services with low debt, post-IPO volatility and regulatory risks introduce moderate uncertainty.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highAs a relatively recent public equity, the stock can experience notable price fluctuations based on quarterly execution.
Valuation riskMediumGrowth expectations are priced into the shares, leaving little room for operational missteps.
Competition risk (CVS Omnicare / BrightSpring PharMerica)HighThe company competes against well-resourced healthcare giants with massive purchasing and distribution networks.
Business qualityStrongGuardian operates a specialized, high-retention pharmacy model backed by solid cash flows and clean credit metrics.
Dividend incomeLow / noneIncome-focused investors will find minimal dividend yield as capital is retained for growth.
Execution riskMediumSuccessful growth relies heavily on executing local pharmacy integrations and maintaining strict regulatory compliance.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.14B USD
Price to earnings Ratio 42.32
1Y Target Price 50.14
Price to earnings Ratio 42.32
1Y Target Price 50.14
Volume (30-day avg) 480.1K shares
Beta 0.06
52 Weeks Range 26.34 - 50.59
Updated Date 11/15/2026
52 Weeks Range 26.34 - 50.59
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.17

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 5%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GRDN receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
GRDN has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+156.4%) and solid cash generation (FCF margin 5.6%) are partially offset by soft profitability (net margin 3.4%).

Financial Health Rating

★★★★★
GRDN's financial health is supported by solid cash strength, including free-cash-flow generation (5.6% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is GRDN's strongest growth driver at +156.4% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+17.9%, solid) and free-cash-flow growth (+94.1%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 49.0% and approximately 56.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 45.30% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 5.12%
Wellington Management Company LLP 2.73%
BlackRock Inc 2.49%
Vanguard Capital Management, LLC 2.18%
Woodline Partners LP 2.06%

Unit Economics (Per $1K Revenue)

★★★★★
GRDN generates approximately $195 of gross profit, $61 of operating income, and $56 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins and solid cash conversion support a 3-star rating, while capital efficiency is strong.

Economic Dimensions

★★★★★
Effective Tax Rate: 33.32%

Quantitative Style Profile

★★★★★
GRDN has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Long-Term Care Pharmacy DispensingDispensing prescription medications, customized multi-dose packaging, and clinical consulting services to residents in assisted living, behavioral health, and skilled nursing facilities.This is the core revenue engine, generating recurring cash flow by supplying daily medications to vulnerable resident populations.
Technology & Administrative ServicesProprietary software tools like Guardian Compass that assist facilities with medication tracking, billing support, and regulatory compliance.Adds value for care facility clients, increasing customer retention and embedding Guardian deeply into facility workflows.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.28
Actual 0.3

Profitability

Profit Margin 5.13%
Operating Margin (TTM) 6.47%

Management Effectiveness

Return on Assets (TTM) 13.37%
Return on Equity (TTM) 32.01%

Valuation

Trailing PE 42.32
Forward PE 33.22
Enterprise Value 3.05B
Price to Sales(TTM) 2.15
Enterprise Value 3.05B
Price to Sales(TTM) 2.15
Enterprise Value to Revenue 2.1
Enterprise Value to EBITDA 23.62
Shares Outstanding 63.32M
Shares Floating 35.90M
Shares Outstanding 63.32M
Shares Floating 35.90M
Percent Insiders 45.3
Percent Institutions 48.97

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.